Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Metals drag Indian stock markets
Mon, 16 Jan 09:30 am

Asian stock markets have opened the day on a weak note. Stock markets in Japan (down 1.5%), Singapore (down 1.1%), Hong Kong (down 0.9%), and Indonesia (down 0.6%) are in the red. The Indian stock markets have opened the day on a weak note. Stocks in the metals and consumer durables space are leading the losses.

The BSE-Sensex is trading lower by 40 points (0.3%) and the NSE-Nifty is lower by around 17 points (0.4%). Mid cap and small cap stocks have opened on a mixed note, with the BSE Mid cap index down by 0.1% while BSE Small cap is up by 0.1%. The rupee is trading at Rs 51.7 to the US dollar.

Auto stocks have opened the day on a weak note with Hero MotoCorp and Bajaj Auto in the red. As per a senior official, Chennai-based TVS Motor is planning to ramp up its existing operations of manufacturing two-wheelers at Howrah in West Bengal. It plans to increase the production of motorcycles at the Uluberia plant from 1,600 units to 2.4 lakh units per annum over the next three years. The company would incur a total capex of about Rs 4 bn during this period. Currently TVS has about 100 acres of land at Uluberia which was a result of the joint venture (JV) with Mahabharat Motors of Universal Success. While the company will continue to manufacture two-wheelers on 44 acres of land, on the remaining 56 acres, the JV would set up an auto ancillary unit.

Pharma stocks have opened the day on a weak note with Aurobindo Pharma and Ranbaxy Laboratories in the red while Glenmark Pharmaceuticals in the green. Glenmark Pharmaceuticals expects the sales from its speciality business to grow at 20% in India for the next three years. The speciality division focuses on branded products. The management said that the objective of the India business is to grow 18-20% in CAGR terms. For the company, India, Russia and Brazil will remain the focus markets. The sales of the Glenmark from speciality segment stands at US$ 55 m for the second quarter ended for financial year 2011-2012. The company is planning to build its expertise over therapeutic areas like dermatology, respiratory and oncology, across all regions. Commenting on its generics business Glenmark said that it will launch 4 first-to-file opportunities in the US generics market between March 2012 and December 2016.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Metals drag Indian stock markets". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.